What drugs does Alexion make?
Its products include eculizumab (Soliris) with $4.064 billion in 2020 revenues and ravulizumab (Ultomiris) with $1.076 billion in 2020 revenues, both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq) with $731 million in …
Who makes eculizumab?
It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. It has been developed, manufactured, and marketed by Alexion Pharmaceuticals, which had patent exclusivity until 2017.
What is the difference between Soliris and Ultomiris?
Although they are similar in many respects, a key difference between the two medications is that Ultomiris is not cleared from the body as quickly as Soliris, requiring less frequent infusions.
When was eculizumab FDA approved?
Development Timeline for Soliris
| Date | Article |
|---|---|
| Oct 23, 2017 | Approval FDA Approves Soliris (eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (gMG) |
| Sep 23, 2011 | Approval Soliris (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS) |
When did Alexion go public?
Alexion Pharmaceuticals was founded by Leonard Bell in 1992 at Science Park in New Haven, Connecticut. It became a public limited company in 1996 and was listed in NASDAQ.
Who bought Alexion Pharmaceuticals?
AstraZeneca
AstraZeneca closes mega $39B Alexion buyout despite antitrust fears, making a splash in rare diseases. AstraZeneca’s mega $39 billion takeover of Alexion Pharmaceuticals has come to a close, delivering the British pharma a lucrative portfolio of immunology medicines and a towering presence in rare diseases.
How much does Ravulizumab cost?
It sells for $6543 per vial; the wholesale acquisition cost of ravulizumab is slightly lower at $6404 per vial, the company said in a recent filing, according to Reuters.
How expensive is Soliris?
Priced at $678,392 per year, Soliris is used to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome — blood disorders that result in the destruction of red blood cells. The dosing regimen for Soliris can differ depending on the age of the patient and the condition being treated.
How expensive is Ultomiris?
The cost for Ultomiris intravenous solution (100 mg/mL) is around $6,695 for a supply of 3 milliliters, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
How much does Soliris cost?
Is Soliris an immunosuppressant?
SOLIRIS® (Eculizumab) Immunosuppressant.
Who is CEO of Alexion?
Ludwig N. Hantson (Mar 2017–)
Alexion Pharmaceuticals/CEO
Ludwig N. Hantson, Ph. D., is Chief Executive Officer of Alexion. Dr. Hantson is an accomplished healthcare executive with more than 30 years of experience in the biopharmaceutical industry.
When did Amgen settle with Alexion over eculizumab?
On May 29, 2020, Alexion filed an 8-K with the Securities And Exchange Commission stating that Alexion and Amgen entered into a settlement and license agreement regarding the eculizumab IPRs.
When did the PTAB terminate the eculizumab IPRs?
The same day as the 8-K filing, Amgen and Alexion filed a joint motion to terminate the eculizumab IPRs and the PTAB terminated the proceedings on June 1, 2020. Comments are closed.
How is Soliris used in the treatment of aHUS?
SOLIRIS was the first therapy approved for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. 1 SOLIRIS is approved for the treatment of patients with aHUS in more than 40 countries, including the United States, European Union, and Japan.
How to apply for Alexion OneSource TM copay program?
The Alexion OneSource TM CoPay Program may help patients pay for eligible out-of-pocket medication and infusion costs. Patients can apply for the CoPay Program by filling out the enrollment form at https://alexiononesource.com/CoPayForm.